Pharmacogenetics of pharmacoecology: Which route to personalized medicine?

Clinical Pharmacology and Therapeutics

Volumn 85, Issue 4, 2009, Pages 343-348

  Robertson, G R ^a   Grant, D M ^b   Piquette Miller, M ^b  

^a UNIVERSITY OF SYDNEY   (Australia)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CYTOCHROME P450 1A1; CYTOCHROME P450 2D6;

ALLELE; BIOINFORMATICS; CLINICAL PHARMACOLOGY; DRUG RESPONSE; DRUG UTILIZATION; EDITORIAL; ENVIRONMENTAL FACTOR; EPIGENETICS; GENE EXPRESSION; GENETIC ANALYSIS; GENETIC RISK; HEREDITY; HUMAN; PATIENT MONITORING; PHARMACOGENETICS; PHARMACOGENOMICS; PHENOTYPE; PRIORITY JOURNAL; TUMOR CELL;

ECOLOGY; ENVIRONMENT; GENETIC VARIATION; HUMANS; PHARMACEUTICAL PREPARATIONS; PHARMACOGENETICS;

EID: 62649162338     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2009.17     Document Type: Editorial

References (13)

1. McLachlan, A.J., Hilmer, S.N. & Le Couteur, D.G. Variability in response to medicines in older people: phenotypic and genotypic factors. Clin. Pharmacol. Ther. 85, 431-433 (2009).
2. Giacomini, K. et al. The pharmacogenetics research network: from SNP discovery to clinical drug response. Clin. Pharmacol. Ther. 81, 328-345 (2007).
3. Piquette-Miller, M. & Grant, D.M. The art and science of personalized medicine. Clin. Pharmacol. Ther. 81, 311-315 (2007).
4. Innocenti, F. et al. Genetic variants in the UDPglucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J. Clin. Oncol. 22, 1382-1388 (2004).
5. Gaedigk, A. et al. The CYP2D6 activity score: translating genotype information into a qualitative measure of phenotype. Clin. Pharmacol. Ther. 83, 234-242 (2008).
6. Grossman, I. et al. Genetic determinants of variable metabolism have little impact on the clinical use of leading antipsychotics in the CATIE study. Genet. Med. 10, 720-729 (2008).
7. Schmith, V.D. & Foss, J.F. Effects of inflammation on pharmacokinetics and pharmacodynamics: increasing recognition of its contribution to variability in response. Clin. Pharmacol. Ther. 83, 809-811 (2008).
8. Flexner, C. Pharmacoecology: a new name for an old science. Clin. Pharmacol. Ther. 83, 375-379 (2008).
9. Ozdemir V. et al. Multigenic control of drug response and regulatory decision-making in pharmacogenomics: the need for an upperbound estimate of genetic contributions. Curr. Pharmacogenomics 3, 53-71 (2005).
10. Gomez, A. & Ingelman-Sundberg, M. Pharmacoepigenetics: its role in interindividual differences in drug response. Clin. Pharmacol. Ther. 85, 426-430 (2009).
11. Lesko, L.J. The critical path of warfarin dosing: finding an optimal strategy using pharmacogenetics. Clin. Pharmacol. Ther. 84, 301-303 (2008).
12. Clayton, T.A. et al, Pharmaco-metabonomic phenotyping and personalized drug treatment. Nature 440,1073-1077 (2006).
13. Gramolini, A.O., Peterman, S.M. & Kislinger, T. Mass spectrometry-based proteomics: a useful tool for biomarker discovery? Clin. Pharmacol. Ther. 83, 758-760 (2008).